Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Church who wrote (1000)	7/17/1997 4:40:00 PM
From: JOHN W.	of 6136

***********FLASH********FLASH************* JUNE IMS DATA: 1. VIRACEPT GAINED SIGNIFICANT MARKET SHARE DURING JUNE, CAPTURING 20% OF SCRIPS FROM 14% IN MAY AT THE EXPENSE OF CRIXIVAN. 2. CRIX DECLINED TO 49% IN JUNE FROM 55% IN MAY. 3. NORVIR AND INVIRASE WERE STABLE AT 11% AND 20%. 4. THE REAL STORY IS NEW SCRIPS: VIRACEPT: 29%. CRIXIVAN: 33%. 5. NELF TOTAL SCRIPS FOR JUNE WERE 25,000 UP 23% FROM MAY. 6. MORE DATA WILL BE RELEAED ON CROSS RESISTANCE IN SEPT AT THE ICAAC. 7.PLEASE NOTE; GUIDELINES FOR ANTIRETROVIRAL TREATMENT BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PROVIDES A LIST OF POTENTIAL ALTERNATE THERAPIES FOR SWITCHING UPON DEVELOPING RESISTANCE. TREATMENT WITH NELF OFFERS THE MOST NUMBER OF OPTIONS AS FIRST LINE THERAPY COMPARED TO THE OTHER PI'S. The Gay community will get the truth before Geneva. Look who sponsored today's conference. AIDS activist have had problems with Merck before, and will not appreciate this "conservative position". Look at the numbers, Viracept is destroying Crixivan. Investors of AGPH who are long are trying to add to their positions while they still can and are hoping for a correction as am I. Regards, John.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next